Navigation Links
Trovagene, Inc., Announces Third Quarter and Year to Date Earnings, Provides Milestone Update

SAN DIEGO, Nov. 14, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three and nine months ended September 30, 2012. The Company has a cash balance of $7.8 million as of September 30, 2012.


"The Company has demonstrated continued progress in its cancer detection and infectious disease development programs. We are on track to offer  our first molecular diagnostic test for the detection of oncogene mutations in the urine of cancer patients as well as a proprietary urine-based HPV test  by the end of the year," said Antonius Schuh, Ph.D., chief executive officer of Trovagene.

Third Quarter Financial ResultsFor the third quarter ended September 30, 2012, Trovagene reported a loss of $0.660 million, or $0.05 per share, as compared to a loss of $0.001 million, or $0.00 per share, for the same period in 2011. The increase is primarily due to increased research and development costs and general and administrative expenses during the third quarter of 2012 as compared to the prior year comparable period. In addition, during the third period of 2012, Trovagene received a milestone payment of $0.150 million and during the third period of 2011, the Company experienced a gain from extinguishment of debt of $0.623 million.

Year to Date Financial ResultsNet loss for the nine months ended September 30, 2012 is $5.268 million or $0.42 per share, as compared to a loss of $1.021 million, or $0.11 per share for the nine months ended September 30, 2011. The increase in net loss is attributable to a number of factors, including: a loss of $1.825 million from the change in fair value of derivative instruments – warrants – during the nine months ended September 30, 2012, an increase in the total costs and expenses during the third quarter of 2012 as compared to the prior year comparable period, and a gain from extinguishment of debt of $0.623 million during the third period of 2011.

Cash and Cash EquivalentsTrovagene had cash and cash equivalents of $7.8 million at September 30, 2012, as compared to $0.7 million at December 31, 2011. The increase in cash is primarily the net result of cash provided by financing activities, including net proceeds of $9.1 million received from an underwritten public offering of our common stock and warrants in June 2012.

Review of Recent Announcements Demonstrates Progress in Development Programs

  • Finalized agreement with Strand Life Sciences Pvt Ltd of Bangalore, India to validate and commercialize our proprietary urine-based Human Papillomavirus  (HPV) test in India and South Asia
  • Granted Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services related to acute myelogenous leukemia (AML).
  • Achieved intellectual property milestone under license agreement with Ipsogen. Issuance of first U.S. NPM1 patent triggered milestone payment.
  • About Trovagene, Inc.

    Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.(Financial Information to Follow)ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

    Chief Financial OfficerAmy Caterina

    Investor RelationsTrovagene, Inc.Trovagene, Selected Financial Information

    Consolidated Condensed Statements of Operations



    (in thousands, except for per share amounts)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2012201120122011Revenues$





    224Operating expenses:  Research and development 5112011,326602  General and administrative 7395862,3761,721Total operating expenses1,2507873,7022,323Loss from operations(1,039)(732)(3,415)(2,099)Other income (expense)---(57)  Gain on extinguishment of debt-623-623  Change in fair value of derivative instruments - warrants 389118(1,824)541Net (loss) income and comprehensive  (loss) income$




    (992)  Preferred stock dividend(10)(10)(29)(29)Net loss available to common shareholders$




    (1,021)Basic and diluted net loss per share$







    Weighted average shares outstanding14,178 


    9,401 Consolidated Condensed Balance Sheet Information

    (in thousands)September 30,2012December 31,2011Cash and cash equivalents$


    700Other assets548316Property and equipment, net20823Total assets$


    1,039Accounts payable, accrued expenses and other liabilities$


    1,430Derivative financial instruments2,8383,840Stockholders' equity (deficiency)4,975(4,231)Total liabilities and stockholders' equity (deficiency)$



    SOURCE Trovagene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
    2. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
    3. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
    4. Dynamic Healthcare Services Acquires Evanko Respiratory Inc., a Provider of Medical Equipment and Respiratory Therapy Products and Services in Hazleton, PA
    5. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
    6. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
    7. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
    8. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
    9. Fetal Surveillance Company, PeriGen, Inc., to Collaborate with National Institute of Child Health and Human Development to Research Fetal Heart Rate Patterns During Labor
    10. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
    11. Huntzinger Management Group, Inc., (HMG) Reporting Significant Growth in 2012
    Post Your Comments:
    (Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
    (Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
    (Date:11/30/2015)... Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 , ... 384,242 , 9.8 Hospital Management Service Income ... (18.3) Medical Insurance Administration Service Income , 2,780 ... and Accessories Sales , 89,645 , 94,580 ... 2,822 , 2,917 , (3.3) Gross ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... ... annual fundraising campaign to raise funds for its research, education, support, and advocacy ... the organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes ...
    (Date:11/30/2015)... ... ... running, and walking are regular Sunday activities for many South Floridians, but their physical ... That’s when the 7th annual ANF Group Tour de Broward will take place at ... Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored by ANF Group, consists ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , ... to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA ... night’s sleep. ChiliPad precisely regulates the surface temperature of each side of the ...
    (Date:11/30/2015)... ... 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... He has both advanced training and considerable experience in reconstructive dentistry with attention ... cosmetic dentistry. He is an active Spear Education member providing full mouth ...
    (Date:11/30/2015)... ... , ... Two years ago, Debbie Gregory, the CEO of, found herself ... Meditation (TM). After encouraging a number of veterans to go through the program, ... the talk. , TM is becoming one of the best alternative treatments for Post-Traumatic ...
    Breaking Medicine News(10 mins):